mRNA Vaccines

Dong Yu · Benjamin Petsch

gen 2023 · Current Topics in Microbiology and Immunology Libro 437 · Springer Nature

Ebook

205

pagine

Valutazioni e recensioni non sono verificate Scopri di più

Informazioni su questo ebook

The formulation and the technological advancements in RNA biology, chemistry, stability, and encapsulated delivery systems that have enabled the development of fully synthetic mRNA vaccines are discussed in this volume. The applications of the mRNA technology is covered, focusing on infectious diseases but also touching on other indications, such as immunotherapies and molecular therapies. Potent and long-lasting immune responses observed in animal models, encouraging data from early human clinical studies, together with the success of two mRNA-based COVID-19 vaccines support the use of mRNA-based vaccination as an attractive alternative to conventional vaccine approaches. Consequently, the development progress of the technology, particularly on production, capabilities, and clinical development is reviewed. Topics on safety, regulatory issues, and possible challenges to the mRNA vaccination approach round off this book. Thanks to their high potency, the prospect for generic, low-cost manufacturing processes, and entirely synthetic nature, the future for mRNA vaccines is highly promising. Importantly, mRNA vaccines have the potential to minimize the time between pathogen identification and vaccine release with a huge impact on public health.

As the mRNA-based vaccination technology has been progressing rapidly, the book is intended to be an end-to-end review series, covering everything from basic RNA biology and preclinical studies to the manufacturing strategy, clinical development and regulatory approval. It provides established RNA researchers and developers with updates on the latest advancements in the field and allows for a quick but comprehensive overview of this transformative technology, its application, and future potential.

Informazioni sull'autore

Dr. Dong Yu currently is Senior Vice President of Research at Dynavax Technologies. Prior to joining Dynavax, Dr. Yu was the Head of Preclinical R&D US at GSK Vaccines. He received the PhD from University of Connecticut Health Center. He was a faculty member at Washington University in Saint Louis and the Head of Microbial Molecular Biology at Novartis Vaccines prior to joining GSK Vaccines in 2015. Dr. Yu authored over 40 publications in various journals and books. His publications reflect his research interests in virology, infectious diseases, and vaccines.

Dr. Benjamin Petsch, Senior Director Prophylactic Vaccine Research at CureVac AG, Benjamin Petsch joined CureVac in 2010 as a scientist in the vaccines department developing mRNA based vaccines against infectious diseases and is heading the department since 2013. He received his university degree from Ludwig-Maximilians-University of Munich and performed his doctoral thesis at the Friedrich-Loeffler-Institut, Tübingen, where he continued as a postdoc and research group leader working on mRNA vaccination against Influenza and on intervention of Influenza replication using small molecules. Dr. Petsch has a 10+ years scientific experience on mRNA based prophylactic vaccines.

Valuta questo ebook

Dicci cosa ne pensi.

Informazioni sulla lettura

Smartphone e tablet

Installa l'app Google Play Libri per Android e iPad/iPhone. L'app verrà sincronizzata automaticamente con il tuo account e potrai leggere libri online oppure offline ovunque tu sia.

Laptop e computer

Puoi ascoltare gli audiolibri acquistati su Google Play usando il browser web del tuo computer.

eReader e altri dispositivi

Per leggere su dispositivi e-ink come Kobo e eReader, dovrai scaricare un file e trasferirlo sul dispositivo. Segui le istruzioni dettagliate del Centro assistenza per trasferire i file sugli eReader supportati.

Segnala contenuti illegali